Generalized Anxiety Disorder: Adult: The dose range is 150 to 600 mg per day given as two to three divided doses. The need for treatment should be reassessed regularly.
Pregabalin treatment can be started at a dose of 150 mg per day. Based on individual patient response and tolerability, the dose may be increased to 450 mg per day. The maximum dose of 600 mg per day may be achieved after an additional 7 days.
Discontinuation of Pregabalin: In accordance with current clinical practice, if pregabalin has to be discontinued it is recommended this should be done gradually over a minimum of 1 week independent of the indication.
Patients with renal impairment: Pregabalin is eliminated from the systemic circulation primarily by renal excretion as unchanged drug. As pregabalin clearance is directly proportional to creatinine clearance, dose reduction in patient with compromised renal function must be individualized according to creatinine clearance (CLcr), as indicated in Table 1 determined using the following formula: See formula.

Pregabalin is removed effectively from plasma by haemodialysis (50% of drug in 4 hours). For patients receiving haemodialysis, the pregabalin daily dose should be adjusted based on renal function. In addition to the daily dose, a supplementary dose should be given immediately following every 4 hours haemodialysis treatment (see Table 1).

Patients with hepatic impairment: No dose adjustment is required for patients with hepatic impairment.
Pediatric population: The safety and efficacy in children below the age of 12 years and in adolescents (12-17 years of age) have not been established. No data are available.
Elderly (over 65 years of age): Elderly patients may require a dose reduction of pregabalin due to a decreased renal function.
Administration: Pregabalin may be taken with or without food.
Pregabalin is for oral use only.